Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension

Hypertension

Volumn 64, Issue 6, 2014, Pages 1241-1247

  Okamoto, Luis E ^a   Gamboa, Alfredo ^a   Shibao, Cyndya A ^a   Arnold, Amy C ^a   Choi, Leena ^b   Black, Bonnie K ^a   Raj, Satish R ^a,b   Robertson, David ^a,b   Biaggioni, Italo ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autonomic nervous system; Hypertension; Nebivolol; Nitric oxide

Indexed keywords

METOPROLOL TARTRATE; NEBIVOLOL; NITRIC OXIDE; SILDENAFIL; SODIUM; BENZOPYRAN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; METOPROLOL;

AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MONITORING; CHRONOTROPISM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSOR RESPONSE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MALE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRESSOR RESPONSE; PRIORITY JOURNAL; PURE AUTONOMIC FAILURE; RANDOMIZED CONTROLLED TRIAL; SHY DRAGER SYNDROME; SINUS ARRHYTHMIA; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; VALSALVA MANEUVER; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASODILATATION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; BENZOPYRANS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; METOPROLOL; NITRIC OXIDE; TREATMENT OUTCOME; VASODILATION;

EID: 84922480106     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04116     Document Type: Article

References (41)

1. Gao Y, Vanhoutte PM. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker. J Cardiovasc Pharmacol. 2012;59:16-21.
2. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205.
3. Kubli S, Feihl F, Waeber B. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation. Clin Pharmacol Ther. 2001;69:238-244.
4. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199-204.
5. Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997;30:1062-1067.
6. Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105:116-124.
7. Jordan J, Shannon JR, Pohar B, Paranjape SY, Robertson D, Robertson RM, Biaggioni I. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol. 1999;10:35-42.
8. Jordan J, Shannon JR, Grogan E, Biaggioni I, Robertson D. A potent pressor response elicited by drinking water. Lancet. 1999;353:723.
9. Shibao C, Gamboa A, Diedrich A, Dossett C, Choi L, Farley G, Biaggioni I. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension. 2007;50:54-61.
10. Man In't Veld AJ, Boomsma F, Schalekamp MA. Effects of beta-adrenoceptor agonists and antagonists in patients with peripheral autonomic neuropathy. Br J Clin Pharmacol. 1982;13(Suppl 2):367S-374S.
11. Man In'T Veld AJ, Schalekamp MA. Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension. BMJ. (Clin Res Ed). 1981;283:561.
12. Gamboa A, Shibao C, Diedrich A, Paranjape SY, Farley G, Christman B, Raj SR, Robertson D, Biaggioni I. Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure. Hypertension. 2008;51:1531-1536.
13. Kaufmann H. Consensus statement on the defnition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. 1996;6:125-126.
14. Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin. 2002;20:291-301, vii.
15. Robertson D. Assessment of autonomic function. In: Baughman KL, Greene BM, eds. Diagnostic Manual for the House Officer. Baltimore: Williams & Wilkins; 1981:86-131.
16. Mosqueda-Garcia R. Evaluation of autonomic failure. In: Robertson D, Biaggioni I, eds. Disorders of the Autonomic Nervous System. London, UK: Harwood Academic Publishers; 1995:25-59.
17. Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, Biaggioni I. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension. 2013;61:701-706.
18. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-220.
19. Triposkiadis F, Giamouzis G, Kelepeshis G, Sitafidis G, Skoularigis J, Demopoulos V. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int J Clin Pharmacol Ther. 2007;45:71-77.
20. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
21. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491-1499.
22. Okamoto LE, Shibao C, Gamboa A, Choi L, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I. Synergistic effect of norepinephrine transporter blockade and a-2 antagonism on blood pressure in autonomic failure. Hypertension. 2012;59:650-656.
23. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-1349.
24. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295-1302.
25. Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, Ocampo O. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol. 2000;35:45-50.
26. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
27. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfeld M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
28. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (cafe) study. Circulation. 2006;113:1213-1225.
29. Polónia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit. 2010;15:235-239.
30. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, Zilmer M, Eha J. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122-1128.
31. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
32. Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460-463.
33. Ladage D, Brixius K, Hoyer H, Steingen C, Wesseling A, Malan D, Bloch W, Schwinger RH. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006;33:720-724.
34. Eeftinck Schattenkerk DW, Van Den Bogaard B, Cammenga M, Westerhof BE, Stroes ES, Van Den Born BJ. Lack of difference between nebivolol/hydrochlorothiazide and metoprolol/hydrochlorothiazide on aortic wave augmentation and central blood pressure. J Hypertens. 2013;31:2447-2454.
35. Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol. 1996;51:259-264.
36. Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, Biaggioni I. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101:2710-2715.
37. Kronenberg MW, Forman MB, Onrot J, Robertson D. Enhanced left ventricular contractility in autonomic failure: assessment using pressurevolume relations. J Am Coll Cardiol. 1990;15:1334-1342.
38. Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K, Goto C, Oshima T, Yoshizumi M, Chayama K. PDE5 inhibitor sildenafl citrate augments endothelium-dependent vasodilation in smokers. Hypertension. 2003;41:1106-1110.
39. Maule S, Milan A, Grosso T, Veglio F. Left ventricular hypertrophy in patients with autonomic failure. Am J Hypertens. 2006;19:1049-1054.
40. Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000;355:725-726.
41. Garland EM, Gamboa A, Okamoto L, Raj SR, Black BK, Davis TL, Biaggioni I, Robertson D. Renal impairment of pure autonomic failure. Hypertension. 2009;54:1057-1061.